Keep a close eye on Mosaic Co. (MOS). The company has raised its profit forecast.
MOS said that demand for potash and phosphates exceeded its expectations in the fourth quarter 2014, and now expects to earn between $0.83 and $0.88 per diluted share (excluding notable items) for the period, above analysts' average estimate of $0.58 per share.
MOS expects further business strength as it moves into 2015, with strong demand for potash and phosphates continuing.
MOS is one of the world's leading producers and marketers of concentrated phosphate and potash crop nutrients. It is a single source provider of phosphate and potash fertilizers and feed ingredients for the global agriculture industry.
More about the Mosaic Company (MOS) at www.mosaicco.com.
**
Psoriasis is a common, chronic, relapsing, immune-mediated, inflammatory disorder with primary involvement of the skin and a strong genetic predisposition. The World Psoriasis Day consortium estimates that 125 million people worldwide - 2 to 3% of the total population - have psoriasis
Psoriasis develops when a person’s immune system sends faulty signals that tell skin cells to grow too quickly. New skin cells form in days rather than weeks. The body does not shed these excess skin cells. The skin cells pile up on the surface of the skin, causing patches of psoriasis to appear. The disorder varies in severity from minor localised patches to complete body coverage.
Plaque psoriasis is the most common type of psoriasis. About 80% of people who develop psoriasis have plaque psoriasis, which appears as patches of raised, reddish skin covered by silvery-white scales. These patches, or plaques, frequently form on the elbows, knees, lower back, and scalp.
According to the National Psoriasis Foundation, up to 30% of people with psoriasis develop psoriatic arthritis, a painful, chronic inflammatory disease characterised by pain, stiffness, swelling and tenderness of the joints, inflammation in places where specific ligaments and tendons attach to bones, and decrease in physical functioning
Psoriatic arthritis can affect any joint in the body, and it may affect just one joint, several joints or multiple joints, and can occur in people without skin psoriasis, particularly in those who have relatives with psoriasis. It can impact the ability to perform day-to-day activities and has been reported to increase work disability.
Celgene Corporation's (CELG) wholly-owned subsidiary Celgene International Sàrl reported that the European Commission, which represents the interests of the European Union as a whole (not the interests of individual countries), has granted marketing authorisation for OTEZLA(R) (apremilast) for two therapeutic indications:
- For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light
- Alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy
CELG's OTEZLA, a selective inhibitor of phosphodiesterase 4 (PDE4), is the first oral treatment in 20 years to receive approval for patients with psoriasis and in the last 15 years to receive approval for psoriatic arthritis. CELG said that OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
CELG is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
More about Celgene Corporation (CELG) at www.celgene.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Corona, CA ( www.corona.crwe-pr.com ) into the CRWE Network.
Corona is located in Southern California in Riverside County, approximately 45 miles southeast of Los Angeles in western Riverside County. It is near the Cleveland National Forest and in a region that is known as the "Inland Empire". The Corona community boasts many amenities that provide a first-rate quality of life for residents.
The City of Corona had an estimated population in 2013 (U.S. Census Bureau) of 159,503, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
MOS said that demand for potash and phosphates exceeded its expectations in the fourth quarter 2014, and now expects to earn between $0.83 and $0.88 per diluted share (excluding notable items) for the period, above analysts' average estimate of $0.58 per share.
MOS expects further business strength as it moves into 2015, with strong demand for potash and phosphates continuing.
MOS is one of the world's leading producers and marketers of concentrated phosphate and potash crop nutrients. It is a single source provider of phosphate and potash fertilizers and feed ingredients for the global agriculture industry.
More about the Mosaic Company (MOS) at www.mosaicco.com.
**
Psoriasis is a common, chronic, relapsing, immune-mediated, inflammatory disorder with primary involvement of the skin and a strong genetic predisposition. The World Psoriasis Day consortium estimates that 125 million people worldwide - 2 to 3% of the total population - have psoriasis
Psoriasis develops when a person’s immune system sends faulty signals that tell skin cells to grow too quickly. New skin cells form in days rather than weeks. The body does not shed these excess skin cells. The skin cells pile up on the surface of the skin, causing patches of psoriasis to appear. The disorder varies in severity from minor localised patches to complete body coverage.
Plaque psoriasis is the most common type of psoriasis. About 80% of people who develop psoriasis have plaque psoriasis, which appears as patches of raised, reddish skin covered by silvery-white scales. These patches, or plaques, frequently form on the elbows, knees, lower back, and scalp.
According to the National Psoriasis Foundation, up to 30% of people with psoriasis develop psoriatic arthritis, a painful, chronic inflammatory disease characterised by pain, stiffness, swelling and tenderness of the joints, inflammation in places where specific ligaments and tendons attach to bones, and decrease in physical functioning
Psoriatic arthritis can affect any joint in the body, and it may affect just one joint, several joints or multiple joints, and can occur in people without skin psoriasis, particularly in those who have relatives with psoriasis. It can impact the ability to perform day-to-day activities and has been reported to increase work disability.
Celgene Corporation's (CELG) wholly-owned subsidiary Celgene International Sàrl reported that the European Commission, which represents the interests of the European Union as a whole (not the interests of individual countries), has granted marketing authorisation for OTEZLA(R) (apremilast) for two therapeutic indications:
- For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light
- Alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy
CELG's OTEZLA, a selective inhibitor of phosphodiesterase 4 (PDE4), is the first oral treatment in 20 years to receive approval for patients with psoriasis and in the last 15 years to receive approval for psoriatic arthritis. CELG said that OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
CELG is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
More about Celgene Corporation (CELG) at www.celgene.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Corona, CA ( www.corona.crwe-pr.com ) into the CRWE Network.
Corona is located in Southern California in Riverside County, approximately 45 miles southeast of Los Angeles in western Riverside County. It is near the Cleveland National Forest and in a region that is known as the "Inland Empire". The Corona community boasts many amenities that provide a first-rate quality of life for residents.
The City of Corona had an estimated population in 2013 (U.S. Census Bureau) of 159,503, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
